Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 301-308

  Piedbois, Pascal ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FOOT DISEASE; HAND DISEASE; HUMAN; INFUSION SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYNDROME; VOMITING;

EID: 0344109583     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.301     Document Type: Article

References (29)

1. Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in ternis of response rate. J Clin Oncol 10:896-903, 1992
2. Advanced Colorectal Cancer Meta-analysis Project: Metaanalysis of randomized trials testing the biochemical modulation of 5-fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 12:960-969, 1994
3. Myers CE, Diasio R, Eliot HM, et al: Pharmacokinetics of the fluoropyrimides: Implications for their clinical use. Cancer Treat Rev 3:175-183, 1975
4. Fraile RJ, Baker LH, Buroker TR, et al: Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 40:2223-2228, 1980
5. Aschele C, Sobrero A, Faderan MA, et al: Novel inechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52:1855-1864, 1992
6. Carlson R: Continuous intravenous infusion chemotherapy, in Perry MC (ed): The Chemotherapy Source Book. Baltimore, MD, Williams & Wilkins, 1996, pp 225-251
7. Lokich JJ, Bothe A, Fine N, et al: Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 48:2565-2568, 1981
8. Leichman L, Leichman CG, Kinzie J, et al: Long-term low dose 5-fluorouracil in advanced measurable colon cancer: No correlation between toxicity and efficacy. Proc Am Soc Clin Oncol 4:333, 1985 (abstr)
9. Belt RJ, Davidner ML, Myron MC, et al: Continuous low dose 5-fluorouracil for adenocarcinoma: Confirmation of activity. Proc Am Soc Clin Oncol 4:349, 1985 (abstr)
10. Seifert P, Baker LH, Reed ML, et al: Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36:123-128, 1975
11. Hansen RM. Ryan L, Anderson T, et al: Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 88:668-674, 1996
12. Weinerman B, Shah A, Fields A, et al: Systemic infusion versus bolus chemotherapy in measurable colorectal cancer. Am J Clin Oncol 15:518-523, 1992
13. Leichman CG, Fleming TR, Muggia FM, et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13:1303-1311, 1995
14. Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 7:425-432, 1989
15. Rougier P, Paillot B, Laplanche A, et al: End results of a multicenter randomized trial comparing 5-FU in continuous systemic infusion to bolus administration in measurable metastatic colorectal cancer. Proc Am Soc Clin Oncol 11:465, 1992 (abstr)
16. Isacson S: 5-fluorouracil and folinic acid in the treatment of colorectal carcinoma: A randomized trial of two different schedules of administration. Second International Conference on Gastro-Intestinal Cancer, Jerusalem, Israel, 1989
17. DerSimonian R, Charette LJ, McPeek B, et al: Reporting on methods in clinical trials. N Engl J Med 306:1332-1337, 1982
18. Chalmers TC, Celano P, Sacks HS, et al: Bias in treatment assignment in controlled clinical trials. N Engl J Med 309:1358-1361, 1983
19. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
20. Meta-analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of non resectable liver metastases from colorectal cancer. J Natl Cancer Inst 88:252-258, 1996
21. Mantel H, Haenzel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
22. Cox DR: The Analysis of Binary Data. London, United Kingdom, Methuen, 1970
23. Peto R, Pike MC, Armitage P, et al: Design and analysis of randomized clinical trials requiring prolonged observation of each patient (II. analysis and examples). Br J Cancer 35:1-39, 1977
24. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
25. Slud EV: Confidence limits for median survival time of censored and uncensored data. Biometrics 40:587-600, 1984
26. Buyse M, Piedbois P: Meta-analyses, use and misuse. J Clin Oncol 11:382, 1993 (letter)
27. Conroy T, Adenis A, Brucker P, et al: A prospective randomized trial of protracted infusional 5 FU with allopurinol versus bolus 5 FU and high-dose leucovorin in metastatic colorectal cancers. Proc Am Soc Clin Oncol 11:462, 1992 (abstr)
28. Buyse M, Piedbois P: On the relationship between response to treatment and survival time. Stat Med 15:2797-2812, 1996
29. O'Connell M, Martenson JA, Wieand HS, et al: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331:502-507, 1994